DOORwaY90: Selective Internal Radiation Therapy using SIR-Spheres Y-90 Resin Microspheres as first-line treatment for unresectable Hepatocellular Carcinoma patients (NCT04736121)

Sunday, April 12, 2026

3:54 PM - 4:03 PM ET

Location: 718B

Presenting Author(s)

Armeen Mahvash, MD

Physician
MD Anderson Cancer Center, United States

Author/Co-author(s)

Ammar Sarwar, MD, FSIR (he/him/his)

Professor of Radiology
University of Pittsburgh Medical Center, United States
Gregory J. Nadolski, MD

MD
Hospital of the University of PA, United States
Nima Kokabi, MD

Associate Professor of Radiology
University of North Carolina - Chapel Hill, United States
EW

Eric Wehrenberg-Klee, MD

Interventional Radiologist
Massachusetts General Hospital, United States
DM

Douglas A. Murrey, Jr., MS, MD

Interventional Radiologist
Inland Imaging, United States
Ripal Gandhi, MD, FSIR

Professor
Miami Cardiac & Vascular Institute, Miami Cancer Institute, United States
Cheenu Kappadath, PhD

Professor
University of Texas MD Anderson Cancer Center, United States

Purpose:

DOORwaY90, a prospective, multicenter, open-label, single-arm study, evaluated the safety and efficacy of 90Y-resin microspheres as first-line treatment for local tumor control in unresectable HCC. This is the first prospective study of 90Y-resin microspheres using personalized dosimetry, imaging-based treatment dose verification, and independent centralized review for response assessment.

Materials and Methods:

All patients enrolled in DOORwaY90 (N=100) completed a minimum of 12 months of safety follow-up. Inclusion criteria: HCC ineligible for resection or ablation, BCLC A-C, maximal single lesion size ≤8 cm, sum of diameters ≤12 cm.100 patients (121 target tumors) from 18 centers were treated using partition dosimetry (T/N=1 for segmentectomies) to target mean tumor dose 150-400 Gy.

Results:

Median treated tumor size was 2.8 cm (range 1-8 cm). Median tumor dose delivered was 513 Gy. Xx% (x/y) of patients had a Best Objective Response through 9 months (pre-specified goal >40%). XX% (x/y) had a ≥6 month duration of response (pre-specified goal >60%). Follow-up imaging showed no local tumor progression in any patients. The most commonly occurring all-grade AEs were fatigue, abdominal pain, and vomiting, which occurred in X%, X%, and X% of patients, respectively. X procedure-related SAEs were reported for X out of 100 patients.

Conclusion:

DOORwaY90 is the first prospective study in HCC with partition dosimetry as well as independent central review. All but one patient had a response and no patients experienced progression in Y-90-treated tumors.